Endocyte Announces Third Quarter 2017 Earnings Conference Call
October 30, 2017 16:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Monday, Nov. 6th, at 4:30 p.m. EST to discuss...
Endocyte Announces Exclusive Worldwide License of Phase 3 Ready PSMA-Targeted Radioligand Therapy for Development in Prostate Cancer
October 02, 2017 07:30 ET
|
Endocyte, Inc.
- Transformational Transaction Provides Endocyte with the Most Advanced Targeted Radioligand Therapy in Development for Prostate Cancer, Addressing a Greater than $1 Billion Market Opportunity - - ...
Endocyte to Present at the 2017 Cantor Global Healthcare Conference
September 19, 2017 16:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...
Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release Syndrome Related to CAR T-Cell Therapy
September 06, 2017 08:00 ET
|
Endocyte, Inc.
– Poster further demonstrates the potential of Endocyte’s SMDC CAR-T platform to more safely regulate CAR-T therapy for solid tumors – – Unwanted toxicities may be controlled through the...
Endocyte Announces Presentation at the European Society for Medical Oncology (ESMO)
September 05, 2017 16:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...
Endocyte Announces Presentations at the 254th American Chemical Society National Meeting & Exposition
August 16, 2017 08:00 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...
Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update
August 08, 2017 16:01 ET
|
Endocyte, Inc.
- Plans to Initiate Clinical Development for CAR T-Cell Program in Osteosarcoma in 2018 – - Nearing Completion of Enrollment of Expansion Phase of EC1169 Trial in Prostate Cancer Patients – - IND...
Endocyte Announces Second Quarter 2017 Earnings Conference Call
August 01, 2017 16:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Tuesday, Aug. 8th, at 4:30 p.m. EDT to discuss...
Endocyte Announces Clinical Updates for EC1456 and EC1169
June 02, 2017 08:02 ET
|
Endocyte, Inc.
- Company Continuing EC1169 Program in Taxane-Exposed Patients, but Ending Clinical Development of EC1456 and of EC1169 in Taxane-Naïve Patients - - Refocusing Efforts on Chimeric Antigen...
Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2017 16:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., May 26, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...